PDCD1 and mature T-cell and NK-cell non-Hodgkin lymphoma: Geptanolimab and nivolumab, which are also anti-PD-1 antibodies, have been studied in R/R PTCL with an ORR of 40.4% and 33%, respectively (119, 120).